Immuneel Therapeutics
Immuneel Therapeutics, founded in 2018, is an Indian clinical stage startup focused on developing affordable cell therapies, including pioneering CAR-T cell therapy, to address cancer treatment needs in India.
Founding of Immuneel Therapeutics
Immuneel Therapeutics was founded in 2018 as a privately-owned clinical stage startup company in India. Since its inception, the company has focused on pioneering cell and gene therapies, with an emphasis on making these therapies affordable and accessible to the Indian population.
Cell Therapy Innovations
Immuneel Therapeutics is at the forefront of innovative cell and gene therapies in India. One of their significant advancements is in Chimeric Antigen Receptor T cell therapy (CAR-T cell therapy), a treatment showing promise for cancer patients. The company is working to address the unmet needs of India's growing cancer population through these cutting-edge therapies.
Clinical Trials and Research
Immuneel Therapeutics is conducting India's first Phase 2 trial for CD19 CAR-T (IMN-003A) aimed at treating B cell malignancies. With a focus on cellular immunotherapy platforms and technologies, the company collaborates globally to advance research in the field. These efforts demonstrate Immuneel's commitment to pioneering research and development in cancer treatments.
Awards and Recognition
Immuneel Therapeutics has received notable recognition for its contributions in the cell and gene therapy sector. The company won the 'Most Promising Cell & Gene Therapy Startup in APAC' at the Asia Pacific Cell & Gene Therapy Excellence Awards 2023. Additionally, it was honored as one of 'Biopharma's most promising startups 2023' at the Endpoints 11 Awards event, further cementing its reputation in the industry.